Kornimate/medical-research-clean huggingface dataset:
effect of antithrombotic treatment in patients with both coronary heart disease and atrial fibrillation

Conditions: Atrial Fibrillation; Coronary Heart Disease

Summary: the optimal antithrombotic treatment for coronary heart disease (chd) patients combined with atrial fibrillation (af) is unresolved at present. although the european and american guidelines have given a hand for us, there is absence of real-world data on the safety and efficacy of antithrombotic therapy in asian populations. only a few clinical trials are available to guide difficult decision on antithrombotic therapy in patients with combined af and chd，the investigators highlight the need for the rapid development of clinical trials to close the large gaps in evidence. this research aims to know the real-world use of antithrombotic treatment and clinical prognosis in coronary heart disease patients complicated with atrial fibrillation.

1. our study is an observational, retrospective study. 2. key date elements and definition of each variable were in line with the american heart association(aha)/european society of cardiology(ecs） recommendation on af and chd. to reflect the contemporary antithrombotic management of af and chd in the past five years, the following data were collected: basic socio-demographic information, symptoms and signs relating to af, medical history, results of physical examination and laboratory test. 3. follow-up time is at least 12 months. the patients will be asked about their medications and clinical outcomes by telephone interview or outpatient clinic. then we will analyze the relative safety and efficacy of the various antithrombotic regimens. 4. based on the largest prospective study by denmark about this issue, we anticipate an 30% incidence of composite outcome in the triple therapy arm. to achieve a precision of 10% with an α=0.05 and the rate of defaulters is 10%. the final estimated sample size was 986. 5. henan institute of cardiology epidemiology is responsible for design, date quality control and statistical analysis.

Eligibility criteria:
inclusion criteria: 1. patients with chest pain and a significant lesion \>50% angiographically. 2. patients with a documented af as confirmed by 12 leads ecg or holter ecg. exclusion criteria: 1. rheumatic valvular disease. 2. contraindications to oral anticoagulation. 3. combined with other serious diseases with a life expectancy \< 1 year.

Keywords: atrial fibrillation coronary heart disease antithrombotic treatment clinical prognosis
efficacy and safety of sparc0912 and reference0912 in open angle glaucoma or ocular hypertension

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: a single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of sparc0912 and reference0912. sparc0912 is an experimental drug having similar active ingredient but containing a different preservative as that in reference0912. patients with open angle glaucoma or ocular hypertension will be enrolled and randomly assigned to receive either product. one drop will be instilled to the study eye nightly at 8:00 pm.


Eligibility criteria:
inclusion criteria: * men and women aged ≥ 18 years. * diagnosis of ocular hypertension (oht) or primary open angle glaucoma (poag). * unmedicated iop ≥ 22 mmhg in one or both eyes. * given informed consent. * women of child bearing potential practicing an acceptable method of birth control with a negative urine pregnancy test. exclusion criteria: * known lack of ocular hypotensive response to topical ophthalmic, prostaglandin analogs (in the opinion of the investigator). * intraocular conventional surgery or laser surgery within the past six months. * refractive surgery in study eye (e.g., radial keratotomy, prk, lasik, etc.) within the past 3 months. * angle closure glaucoma or a history of acute angle closure treated with a peripheral iridotomy. * ocular trauma within the past 3 months. * progressive retinal or optic nerve disease apart from glaucoma. * concurrent infectious/non infectious conjunctivitis, keratitis, or uveitis in either eye. * any abnormality preventing stable applanation tonometry. * use of contact lens for the duration of the study. * any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber. * clinically significant ocular disease (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications is not judged safe. * clinically significant systemic disease which might interfere with the study. * history of non-compliance to medical regimens or unwilling to comply with the study protocol. * participation in another clinical study within the last thirty (30) days.

Keywords: glaucoma latanoprost
effects of physical-cognitive training with different task models in parkinson's disease with mild cognitive impairment

Conditions: Mild Cognitive Impairment; Parkinson Disease

Summary: the present study will characterize exercise model effects (integrated model vs. consecutive model) of physical-cognitive exercise on dual-task walking control in parkinson's disease with mild cognitive impairment.


Eligibility criteria:
inclusion criteria: * a diagnosis of idiopathic parkinson's disease * have decreased cognitive functions but do not interfere with functional independence * montreal cognitive assessment (moca): 21-25 * able to walk independently without walking devices for at least 10 meters and with the ability to turn 180° exclusion criteria: * a diagnosis of dementia * other diseases that may influence cognitive functions or walking performance * a history of brain surgery * modification of the medication during the exercise intervention

Keywords: dual-task walking training parkinson's disease mild cognitive impairment electroencephalography
effect of passive exercise on systemic endothelial function in elderly patients with chronic heart failure

Conditions: Congestive Heart Failure; Endothelium-derived Factors; Elderly

Summary: the purpose of this study is to determine the effect of passive exercise on systemic endothelial function in elderly patients with chronic heart failure.

endothelial function is known to be impaired in patients with chronic heart failure (chf) and impaired endothelial function has been reported to be associated with an increased mortality risk in those subjects. although systemic exercise training has been demonstrated to improve endothelial dysfunction in patients with chf, elderly patients with severely impaired exercise capacity could not engaged in usual exercise training using ordinal ergometer. those patients are able to join stretching or very light resistance training. on the other hand, passive pedaling using strength ergometer has been reported to be useful in patients with severely impaired exercise capacity, but the safety and the efficacy of passive pedaling on endothelial function in old patients with chf has not been previously reported.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic heart failure * elderly patients aged ≧65 years * patients with severely reduced exercise capacity and cannot continue exercise with usual cycling ergometer for 5 minutes exclusion criteria: * unstable hemodynamic status (uncontrolled arrhythmia, uncontrolled congestion, uncontrolled hypertension) * active infectious disease * malignancy * chronic obstructive pulmonary disease * dialysis * severe aortic valve disease * with any hip, knee, ankle joint pain * hemiplegia * current smoker

Keywords: passive leg exercise congestive heart failure endothelium-derived factors elderly
role of sphingolipids in pulmonary edema

Conditions: Pulmonary Edema

Summary: in this mono-center prospective study, the impact of changes in the sphingolipid metabolism in patients with pulmonary edema will be investigated.

there will be three groups of patients: 1. hydrostatic pulmonary edema 2. toxic pulmonary edema 3. not ventilated patients without any pulmonary edema samples of a routine bronchoalveolar lavage and edta-blood will be analysed in respect of sphingolipids, ceramide, sphingomyelin-phosphodiesterase and several cytokines.

Eligibility criteria:
inclusion criteria: * above the age of 18 exclusion criteria: * taking steroids

Keywords: sphingolipid ceramide sphingomyelinase
qct in als diagnosis, mechanistic understanding and follow-up

Conditions: Amyotrophic Lateral Sclerosis

Summary: multidisciplinary management of amyotrophic lateral sclerosis (als) can significantly increase survival but also improve the quality of life of patients. the evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. however, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (mep). the combined quadriceps test (qct) has been developed to assess central and peripheral motor pathway conduction. this test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected als, can lead to interpretation problems. the evolution of the qct parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. the study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. this link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. from a prognostic point of view and depending on the quantification of central and peripheral involvement, the qct would make it possible to characterize the different als phenotypes. this phenotypic characterization would help identify prognostic factors at diagnosis. the investigators propose a cohort study with the exploration of central motor neuron damage by qct during the course of als in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis.


Eligibility criteria:
inclusion criteria: * a male or female patient of legal age with suspected als (bulbar or spinal) who meets the criteria for "possible", "probable" or "definite" als according to the awaji criteria * able to give informed consent to participate in the research * enrolled in a social security plan exclusion criteria: * pregnant or breastfeeding woman * severe progressive pathology other than als. * comorbidities with another neurological disease altering motor skills. * contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)... * chronic alcoholism * cognitive disorders or major incapacity making it impossible to understand the study and sign an informed consent (fronto-temporal dementia, psychiatric conditions of psychotic type, language disorders) * refusal to participate. * patients under legal protection (guardianship, curators, safeguard of justice)

Keywords: quadriceps combined test amyotrophic lateral sclerosis
effect of lycopene and isoflavones on glucose metabolism

Conditions: Metabolic Syndrome; Diabetes Mellitus, Non-Insulin-Dependent

Summary: type 2 diabetes mellitus (dm2) is a growing social health problem world-wide, in particular with respect to its contribution to cardiovascular disease. the progressive increase in prevalence of dm2 has reached epidemic proportion and is a major cause of morbidity and mortality in all populations around the world. conventional stepwise treatment of dm2 generally focuses on controlling blood glucose concentration. however, the risk for side-effects associated with the use of pharmacological intervention often delays initiation of therapy, with the potential implication on worsening morbidity and mortality from complications. on the other hand, non-pharmacological intervention in the form of dietary restrictions, exercise and weight loss, is safe but often difficult to accomplish. the availability of nutrients that affect glucose and lipid metabolism would provide an important practical tool to establish early intervention in newly diagnosed dm2 and perhaps even in patients who are only "at risk" for dm2. the investigators have recently obtained preliminary data on beneficial effects of combined supplementation of lycopene and isoflavones on glucose metabolism of normoglycemic volunteers with insulin resistance. this clinical trial will explore the role of isoflavones and lycopene dietary supplementation in the improvement of glucose metabolism of patients at increased risk or with established but mild dm2. the overall hypothesis is that supplementation of laflavon, provided as a new formulation that increases bioavailability of the individual components (laflavon cammedica contains 7 mg of lycopene and 50 mg of soy isoflavones), determines improvement in glucose tolerance and insulin resistance of patients with the metabolic syndrome and also reduces hba1c in patients with mild dm2.


Eligibility criteria:
study group 1( arm 1 ::metabolic syndrome group). inclusion criteria: * age 18-75 years * metabolic syndrome (idf criteria) * stable dose of medications for \> 90 days exclusion criteria: * pharmacological therapy for diabetes * flood allergies, especially to whey protein, soy or tomato. * pregnancy study group 2( arm 2:: diabetes mellitus patients group). inclusion criteria: * 18-75 years of age * type 2 diabetes (diagnosed with ada criteria: fasting plasma glucose \> 125 mg/dl) * stable dose of medications for \> 90 days * patients on diet/exercise, metformin, dd4 inhibitors (sitagliptin and saxagliptin) and /or sulphonylurea for \> 90 days exclusion criteria: * hba1c above 9.5% or below 7.5% in last 3 months * tzd therapy for diabetes * insulin therapy for diabetes * flood allergies, especially to whey protein, soy or tomato * pregnancy
effect of deep versus moderate neuromuscular block during sevoflurane anesthesia on intraoperative surgical conditions.

Conditions: Surgical Conditions

Summary: a deep neuromuscular block (nmb) is often associated with improved surgical conditions especially in laparoscopic surgery. we previously showed that deep nmb is superior to a moderate nmb under propofol anesthesia. however, this may not apply to sevoflurane anesthesia and sevoflurane by itself produces some degree of muscle relaxation. we therefore plan to investigate the effect of deep nmb on surgical conditions under sevoflurane anesthesia maintenance.

neuromuscular blocking agents (nmbas) are routinely administered during general anaesthesia to facilitate endotracheal intubation and to optimize surgical conditions. increasing data suggest superiority of a deep neuromuscular block (defined by a post-tetanic count of 1-2 twitches) in creating optimal working conditions for the surgical team. however, it is unknown whether other aspects of the anaesthetic technique, most notably the choice of anaesthetic (for example, total intravenous versus inhalational anaesthesia), influence the relationship between the depth of the neuromuscular block and surgical conditions, particularly in laparoscopic surgery. volatile anaesthetics are known for their ability to potentiate neuromuscular blocking agents an effect that is less existent with propofol. we previously showed that surgical working conditions in laparoscopic surgery during propofol anaesthesia are highly reliant on the depth of the neuromuscular block. whether such a relationship also exists for inhalational anaesthetics, is unknown. to investigate this, we conducted a prospective, randomized, double blind study in which patients scheduled for laparoscopic renal surgery were randomized to receive either a moderate or a deep neuromuscular block during sevoflurane anaesthesia. the primary outcome was the intraoperative surgical condition assessed by a surgeon using the validated leiden-surgical rating scale. we hypothesized that the use of an inhalational anaesthetic would obviate the need for a deep nmb due to its intrinsic muscle relaxant potentiating properties to produce optimal working conditions.

Eligibility criteria:
inclusion criteria: * patients diagnosed with renal or prostatic disease who are will undergo an elective laparoscopic renal surgical procedure or laparoscopic prostatectomy; * american society of anesthesiologists (asa) class i-iii * \> 18 years of age; * ability to give oral and written informed consent. exclusion criteria: * known or suspected neuromuscular disorders impairing neuromuscular function; * allergies to muscle relaxants, anesthetics or narcotics; * a (family) history of malignant hyperthermia; * women who are or may be pregnant or are currently breast feeding; * renal insufficiency, as defined by glomerular filtration rate \< 30 ml/h creatinine. * previous retroperitoneal surgery at the site of the current surgery. * body mass index \> 35 kg/m2
assessment of fit of novel n95 style transparent face masks

Conditions: Respiratory Disease; Infection, Coronavirus; Respiratory Tract Infections

Summary: face masks have become a critically important public health intervention after the covid-19 pandemic. multiple types of masks ranging from full face filtering to cloth masks have been developed and commercialized to facilitate protection against respiratory pathogens. most of these systems are made with opaque fabrics and may prevent individuals from expressing emotions or for those who are deaf and hard of hearing, communicating. to date, few transparent face masks which also confer respiratory pathogen protection have been developed. this study will test the feasability and acceptability of two new masks, the seeus-95 mask and crystalguard mask which are both transparent versions of n-95 filtering face masks.

this is a randomized crossover trial to evaluate the feasibility, acceptability and choice between the use of the seeus-95, crystalguard transparent face masks or a standard n95 mask. otherwise healthy individuals will be prescreened and then scheduled for a single study visit. participants will be randomized to wear each of the three masks (seeus-95, crystalguard, n95). they will be taught how to wear the mask, and we will assist participants with correctly wearing the mask for a good fit. next, participants will undergo standard fit testing where a clear hood will be placed over the participant's head, and a bitter solution (bitrex) is sprayed into the hood. a positive test is indicated if the participant is able to taste bitrex demonstrating that there is a detected leak within the mask. after a few minute washout period, participants will undergo fit testing of subsequent masks. we will ask participants to rate the comfort of wearing the masks, willingness to wear masks in public and suggestions for improvement in mask design. finally, we will conduct a discrete choice test to ask participants which mask they would prefer to wear in public.

Eligibility criteria:
inclusion criteria: * \>18 years old * no history of asthma, restrictive lung disease, interstitial lung disease, or emphysema * lack of significant facial hair that precludes wearing a n-95 mask exclusion criteria: * less than 18 years old * unable to smell bitrex solution used for fit testing
the pharmacokinetics of zidovudine and oxazepam alone and in combination in the hiv-infected patient

Conditions: HIV Infections

Summary: to determine if a pharmacokinetic (blood level) interaction exists between zidovudine (azt) and oxazepam in the hiv-infected patient. benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. this study is important because of the potential for toxicity resulting from a reaction between azt and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with hiv infection.

benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. this study is important because of the potential for toxicity resulting from a reaction between azt and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with hiv infection. patients are studied to determine oral and intravenous azt and single oral dose oxazepam pharmacokinetics. patients then take azt and oxazepam together to determine if interactions between the drugs occur.

Eligibility criteria:
inclusion criteria concurrent medication: required: * stable prescribed dosage of zidovudine (azt), = or \> 500 mg/day. allowed: * prophylaxis for pneumocystis carinii pneumonia (pcp) with aerosolized pentamidine. * erythropoietin. patients must be: * hiv positive by elisa and western blot. * currently taking a stable prescribed dosage of 500 mg/day of zidovudine (azt). exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * allergy to benzodiazepines or a previously documented intolerance to zidovudine (azt) therapy of = or \< 600 mg/day. * significant underlying medical condition that could impair continuous participation in study. * malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight). concurrent medication: excluded: * oral contraceptives. * cytotoxic chemotherapy. * ganciclovir. * flucytosine. * probenecid. * opiates. * valproic acid. * sulfa drugs. * sucralfate. * dapsone. * rifampin. * antacids within 2 hours of zidovudine (azt) dose. * isoniazid. * ketoconazole. * pyrimethamine. * clindamycin. * aspirin. * ibuprofen. * investigational drugs not specifically allowed. patients with the following are excluded: * allergy to benzodiazepines or a previously documented intolerance to zidovudine (azt) therapy of = or \< 600 mg/day. * significant underlying medical condition that could impair continuous participation in study. * unable to take oral medication reliably. prior medication: excluded within 30 days of study entry: * antiretroviral agents other than zidovudine (azt).

Keywords: oxazepam drug evaluation drug interactions zidovudine